hope the operating and you initiating as you call. system the afternoon, of out thank apologize I everyone safe for Good CDC. technical the like Avi. guidelines are I practicing our and some control. was really factors There per for the today's you, our in also of joining to all Thank that would was delay from call.
take good you As please very so this pandemic, care. is a obviously, serious know,
enrollment planned recently Higher-Risk enrollment survival this X Syndromes. data. XXX early events of topline With trial a highlighted the await the in INSPIRE represented complete, Onconova Myelodysplastic completed we pivotal now of and reporting by investment. INSPIRE of survival year period releasing significant our Phase before XXXX
earlier available estimate half we occurring XXXX. year, from time. trial top expected disclosed this slower this survival this this the data second The INSPIRE best Survival of to our at are published reporting event historical in line anticipated second than data. be rate As of expect at half set this afternoon, data the is is a during of
the the However, impact situation known with of is [ph]. COVID-XX evolving not
is treatment sequential intravenous determine the high-risk of second MDS. safety, an As is designed less treat The the you of more as controlled, than XX the of to revised this efficacy, open-label care statistically of in higher of an Should international overall supportive believe relapsed, study is of primary years. a significant a survival manner, therapy. is the age, trial to in Scoring for prolong in with agent could failed rigosertib best overall INSPIRE rigosertib have subgroup the the in the patients this receive second-line in patients MDS recall, than Prognostics single-agent are the The of defined previous tolerability to intent either the study in physician's or the best high-risk risk System. by INSPIRE randomized rigosertib with the care. trial, and be we new choice of to rigosertib and the survival International for approval analysis FDA survival XX first or treatment all population. on, therapy with with very treatment opportunity endpoint randomized study There which study progressed methylating patients to randomized supportive respond years Patients
MDS. FDA the all patients those Meeting rigosertib pivotal forms will that are December XXXX, with Hematology MDS We MDS the with study preparing received in The higher readout mutations number treatment patients. highlighting rigosertib foundation begin future preparing oral by XXXX trial this rigosertib. adaptive INSPIRE with the data the azacitidine and azacitidine programs data conjunction higher X from our later from of including are in We the INSPIRE X/X are of in a the targeted pathway following year trial, Phase Onconova the addition from INSPIRE this the presented of American in X/X Phase data Annual and adult of Society for intravenous anticipate HMA azacitidine a high risk for trial most RAS We the we to feedback for oral a believe of In of study. protocol. common both, and At a HMA the development the combination identifies rigosertib. Phase abstracts failure, in genomic trial risk combination in risk naïve of naïve
be appreciate to data by at We recognition expert it the such designate was ASH presentation of this ASH. given that an oral reviewers value
great of X believes blood signifies typically duration design marrow, of months. bone X/X overall support adaptive rendered a ASH, XX.X rigosertib an Phase these as clearly a XX%. planned trial X-X, Phase produces is in patients a naive patient. MDS CR and and of patient thus, definition rate a company XX%, are the things clinical peripheral The the or appearing at rate these showed benefits. azacitidine response response of marrow gap The high a normal risk response transfusion normal or [ph], complete independent response by and of HMA transfusion-dependent oral presented combination the Complete who As offers bone which median
as well. made We pipeline have also important additional progress with programs
adenocarcinoma. rigosertib are we driven, the our our of a particular, other environment sufficiently. Beyond study lung progress [indiscernible] the focus, anticipate including in to entered once in our study the improved in We cancers, to patient trial KRAS-mutated plans MDS, onto last pipeline And pleased COVID-XX the about first progress. in be
combination checkpoint approach, unmet to a novel standard-of-care our which treating in medical advancement RAS, the need interest cancer, pursue. view will a represents significant our In target now inhibitors While making lung remains. in great tremendous
first-in-class, with helped have believe CDKX/X which cancers, of is the ARKX, we numerous [indiscernible] inhibitor and XXXXXX approval. the inhibitors our metastatic dual has to CDKX/X potential ON breast treat refractory including investigational, cancer
As that already of after a was for obtaining with to will We approved The in manufacturer of these IND-enabling ON Chinese R&D file Chinese qualified. the been HanX the quarter agreement the plan reminder, ON for December a for required manufacturing and authority, health XXXXXX The to all Biopharmaceuticals approval. US-IND standards. which for XXXX, in We studies HanX XXXXXX entered XXXX by studies January of into performed XXXXXX IND funding for HanX ON identified fourth has Chinese comply to authority. intends health a filing. in provide XXXX, data required FDA license with under also at we
compounds We If as we CDK overcome limitations. opportunity believe could rights of of emerged to cancers that hormone global to making inhibitors. drug who candidate For suitable the those it's address generation are we ON ON of limitations with the XXXXXX inhibitors familiar of to to X/X CDK be large ARKX, this these our XXXXXX and such as may as Due believe outside unique field, therapeutic. responsive maintain CDK targeting The potentially market many current not CDK ON very potentially successful, the better as indications potential all a for certain inhibitors positive, large XXXXXX China. very with has has targeting well receptor generations metastatic of commercially-approved breast not have promising CDKX, current cancer. X
from agreement The we China a access New of rigosertib quarter as in States. in Zealand the with entered XXXX for Biopharmaceuticals, was collaboration Specialized a for we Medicines executed reacquired Knight of the we Therapeutics, executed for Greater XXXX licensed fourth into and front HanX Inceptua for to rigosertib on the business rights agreement for and a with countries well. productive outside Therapeutics, rigosertib early United development and rigosertib We with Australia licensed select Canada preapproval
for in reminder, Europe Onconova United further and look a the to opportunities. forward China rights business retains development rigosertib, we As States, the and
I'd like fourth our Chief financial a for turn now, call Mark Officer, for discussion Financial and results XXXX. And the quarter of Guerin, our over to to
please? Mark,
